The analysis of global non-steroids anti-inflammatory and antirheumatic medicine sales by country reveals significant disparities. In 2023, South Korea led the pack with sales at $17.2 per capita, reflecting a 2.5% increase. Meanwhile, the Czech Republic and Iceland showed modest growth with rises of 0.4% and 3.67% respectively. Germany experienced a decline by 1.18%, and Canada saw a larger drop of 3.17%. On the lower end, Denmark and Austria posted decreases of 5.18% and 1.47%. With Australia and New Zealand showing contrasting trends at -0.72% and 9.24%, this data indicates varied market dynamics across nations.
Future trends to watch for include the potential market growth in New Zealand driven by a 9.24% increase, highlighting an opportunity for expansion in regions showing economic recovery. Monitoring South Korea's continued rise may indicate evolving consumer needs or healthcare policies impacting medicine adoption. A focus on innovating product offerings can further drive sales, especially in countries experiencing a decline. Additionally, keeping an eye on policy changes and healthcare reforms across various regions will offer insight into future market dynamics.
Top countries in Non-Steroids Antiinflammatory and Antirheumatic Medicine Sales by Country
| # | 9 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 South Korea | 17.2 | 2023 | +1.18% | +2.5% | View data |
| 2 | 2 Czech Republic | 15.1 | 2023 | +14.39% | +0.4% | View data |
| 3 | 3 Iceland | 9.7 | 2023 | -1.02% | +3.67% | View data |
| 4 | 4 Germany | 8.2 | 2023 | 0% | -1.18% | View data |
| 5 | 5 Canada | 6.3 | 2023 | 0% | -3.17% | View data |
| 6 | 6 Austria | 5.2 | 2023 | 0% | -1.47% | View data |
| 7 | 7 Denmark | 4.6 | 2023 | -2.13% | -5.18% | View data |
| 8 | 8 Australia | 2.7 | 2023 | 0% | -0.72% | View data |
| 9 | 9 New Zealand | 1.4 | 2023 | 0% | +9.24% | View data |
